Exosomal transmission of viral resistance in Hepatitis B

July 10, 2013 by John Hewitt report
Exosomal transmission of viral resistance in Hepatitis B
Credit: siakhenn.tripod.com

(Medical Xpress)—To move material in bulk, the standard shipping container used by cells, is the vesicle. These approximately 40-micron sized spheres are essentially recyclable grocery bags that can be loaded and adorned with a huge variety of molecules. Exosomes are a particular kind of vesicle that get released when structures known as multivesicular bodies (MSVs) fuse with the plasma membrane. They can potentially be used for diagnostics and perhaps as treatment for many kinds of disease. A paper published in Nature Immunology, has recently shown that exosomes may have a natural function acting against the Hepatitis B virus (HBV). The Chinese authors on the paper have demonstrated that cell-to-cell transmission of the natural antiviral agent, type 1 Interferon (IFN), is mediated by exosomes.

Exosomes have been shown to serve as mediators of intercellular communication and are capable of horizontally transferring mRNA and microRNA. The authors hypothesized that exosomal transfer could explain interferon-induced antiviral responses despite the documented inhibition of interferon-stimulated gene expression by the virus. That is quite a delicate theory applied to a complex system with many diverse players.

IFN, at least the alpha subtype, is given for treatment of chronic HBV infection, but it does not appear to directly inhibit HBV replication. The liver's immune system is composed of , T cells, and its own resident macrophages, the Kupffer cells. The authors used a cell-isolated culture system to determine whether the IFN could be transmitted from these various types of nonparenchymal liver cells to the liver's hepatocytes. In addition, they were able to show that in-vivo exosomal transfer of antiviral molecules against HBV also occurs.

Blocking exosomes increased hepatitis in mice, suggesting perhaps, that augmenting exosome release could be beneficial in treating the disease. Exosomes have been shown to contain a huge variety of anti-viral molecules, which makes it difficult for the virus to deal with all of them together. The authors used a "knockdown and rescue" strategy to further explore the role of nonparenchymal in the antiviral effects of IFN. In particular, they targeted the STAT1 transcriptional activator with a vector encoding short hairpin RNA. The expression products of interferon-stimulated genes under the control of interferon-stimulated response elements were shown to establish an antiviral state in target cells.

The researchers also collected IFN stimulated and unstimulated exosomes by centrifugation and analyzed their components. They used microarray identification of mRNA and microRNA to reveal their differential expression. They hypothesized that the changes reflect preferential sorting of specific exosomal cargo.

The mechanisms by which exosomes are loaded with the proper molecules, when needed, are largely unknown, as is their targeting and timing of release. Neurons have made an art of vesicle communication and perhaps some clues will be found from the study of these, and other, systems. The authors note that the relative importance of different antiviral pathways involving IFN likely depends on the specifics of the virus-host interaction. In addition to the roles of the Kupffer cells demonstrated here, many other cells types are likely to be involved as well.

The manner in which exosomal molecules inhibit HBV is also largely a mystery. It is possible however, that the exosomal method of attack is important in other diseases as well. One study, for example, has reported that APOBEC3G can be packaged and delivered via exosomes to restrict the replication of HIV. Inhibiting exosome release has also been shown to impair the effect of IFN against the adenovirus. The many other dangerous viruses against which we currently have little protection suggests that the study of these new methods of dealing with them may be a worthwhile pursuit.

Explore further: Hepatitis B virus control: Identifying proteins in mutation management

More information: Exosomes mediate the cell-to-cell transmission of IFN-?-induced antiviral activity, Nature Immunology (2013) doi:10.1038/ni.2647

The cell-to-cell transmission of viral resistance is a potential mechanism for amplifying the interferon-induced antiviral response. In this study, we report that interferon-? (IFN-?) induced the transfer of resistance to hepatitis B virus (HBV) from nonpermissive liver nonparenchymal cells (LNPCs) to permissive hepatocytes via exosomes. Exosomes from IFN-?-treated LNPCs were rich in molecules with antiviral activity. Moreover, exosomes from LNPCs were internalized by hepatocytes, which mediated the intercellular transfer of antiviral molecules. Finally, we found that exosomes also contributed to the antiviral response of IFN-? to mouse hepatitis virus A59 and adenovirus in mice. Thus, we propose an antiviral mechanism of IFN-? activity that involves the induction and intercellular transfer of antiviral molecules via exosomes.

Related Stories

Hepatitis B virus control: Identifying proteins in mutation management

June 25, 2013
(Medical Xpress)—Researchers at Kanazawa University Graduate School of Medical Science in Japan have determined how APOBEC proteins mediate hypermutations that inhibit viral replication. They also identify the host factor ...

Virus-like particles provide vital clues about brain tumors

April 17, 2013
Exosomes are small, virus-like particles that can transport genetic material and signal substances between cells. Researchers at Lund University, Sweden, have made new findings about exosomes released from aggressive brain ...

When injected as a hydrogel rather than in solution, an anticancer protein treats liver tumors more effectively

July 3, 2013
Proteins and other therapeutic compounds injected directly into the blood stream tend to be broken down rapidly by the immune system. Now, researchers in Singapore have demonstrated in mice that the anticancer protein, interferon-α2a ...

Novel therapeutic approaches to cure chronic HBV infection

April 25, 2013
Exciting new data presented today at the International Liver Congress 2013 include results from early in vitro and in vivo studies targeting covalently closed circular DNA (cccDNA), which may form the basis of a cure for ...

Novel intercellular transportation system may have potential for delivering RNAi and other gene-based therapeutics

March 27, 2013
(Medical Xpress)—Important new research from UMass Medical School demonstrates how exosomes shuttle proteins from neurons to muscle cells where they take part in critical signaling mechanisms, an exciting discovery that ...

Recommended for you

Genetic immune deficiency could hold key to severe childhood infections

July 18, 2017
A gene mutation making young children extremely vulnerable to common viruses may represent a new type of immunodeficiency, according to a University of Queensland researcher.

What are the best ways to diagnose and manage asthma?

July 18, 2017
What are the best ways to diagnose and manage asthma in adults? This can be tricky because asthma can stem from several causes and treatment often depends on what is triggering the asthma.

Large multi-ethnic study identifies many new genetic markers for lupus

July 17, 2017
Scientists from an international consortium have identified a large number of new genetic markers that predispose individuals to lupus.

Study finds molecular explanation for struggles of obese asthmatics

July 17, 2017
A large, bouquet-shaped molecule called surfactant protein A, or SP-A, may explain why obese asthma patients have harder-to-treat symptoms than their lean and overweight counterparts, according to a new study led by scientists ...

Team identifies potential cause for lupus

July 14, 2017
Leading rheumatologist and Feinstein Institute for Medical Research Professor Betty Diamond, MD, may have identified a protein as a cause for the adverse reaction of the immune system in patients suffering from lupus. A better ...

Immunosuppression underlies resistance to anti-angiogenic therapy

July 14, 2017
A Massachusetts General Hospital (MGH) research team has identified a novel mechanism behind resistance to angiogenesis inhibitors - drugs that fight cancer by suppressing the formation of new blood vessels. In their report ...


Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.